Adaptimmune gets FDA accelerated approval for T cell receptor cell therapy in...
The FDA granted accelerated approval to a cell therapy for synovial sarcoma, a rare type of cancer typically found in the tissue of the arms and legs. Developed by Adaptimmune Therapeutics, it’s the...
View ArticleClik here to view.
Exclusive: Ultragenyx secures first funds for Alzheimer's gene therapy spinout
Rare disease specialist Ultragenyx reeled in a $14 million seed round for its Alzheimer’s gene therapy spinout Amlogenyx, the company exclusively told Endpoints News. The California biotech’s...
View ArticleClik here to view.
Former RayzeBio CEO quickly returns with new biotech; Amgen’s global research...
Ken Song Ken Song is back in business. He left RayzeBio in February after leading the radiopharmaceuticals startup from Series A to IPO in three years, and then a $4.1 billion exit to Bristol Myers...
View ArticleAgios' late-stage Pyrukynd trial in kids with rare blood disorder misses...
Agios’ first-ever pediatric data readout missed the primary endpoint, with its drug Pyrukynd (mitapivat) not showing statistical significance in children with pyruvate kinase (PK) deficiency who are...
View ArticleGalapagos pauses blood cancer CAR-T therapy trial due to one Parkinsonism event
Galapagos has temporarily stopped enrolling patients into an early-phase test in patients with multiple myeloma after a neurological issue was raised. Elsewhere, the biotech expanded its deal with...
View ArticlePARP biotech backed by more than five pharmas closes after nine years
Ribon Therapeutics has shuttered after nine years, and one year after ending its preclinical research to focus on two early-stage PARP programs in cancer and atopic dermatitis. The Cambridge, MA-based...
View Article23andMe board rejects Anne Wojcicki’s take-private plan, requests changes
CEO Anne Wojcicki’s offer to take her genetic testing company 23andMe private for 40 cents a share has been met with resistance from her own board. In a letter sent Friday, a special committee of board...
View ArticleKyowa Kirin divests China unit, prunes discovery and manufacturing work
Kyowa Kirin is selling off its China business and transitioning to a research organization in a shake-up that could lead to major cuts to the company’s in-house discovery and CMC work. The Japanese...
View ArticleApogee and Spyre founder launches another autoimmune biotech, and it's got...
Amid an action-packed Thursday, another biotech launched to take on the ever-popular landscape of autoimmune drug development. And the new Boston-area biotech comes from a repeat creator: Paragon...
View ArticleIn Japan, sales of Eisai and Biogen's Alzheimer's drug begin to accelerate
Biogen and Eisai’s Alzheimer’s drug Leqembi is off to a slow start in the US. But it’s big in Japan. On Friday, Eisai revealed in an investor presentation that Japanese revenue accounted for 1.5...
View ArticleExclusive: Devoted Health raises $112M, plots insurance markets expansion
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Devoted Health just nabbed another $112 million in venture funding to fuel its push into seven new...
View ArticleClik here to view.
Iron chelator therapy unexpectedly worsened Alzheimer’s disease in clinical...
PHILADELPHIA — Among the many mysteries of Alzheimer’s disease is the role that iron plays. The metal is vital for transporting oxygen in the blood and producing energy from mitochondria, but some...
View ArticleMassachusetts' plan for $1B in life science investment stalls in state...
Massachusetts Gov. Maura Healey’s proposal to invest another $1 billion in life sciences over the next 10 years has been imperiled after failing to make it through the state’s legislative body before...
View ArticleShortage of Lilly's blockbuster GLP-1 drugs is over, according to FDA
Eli Lilly’s blockbuster weight loss and diabetes drugs are no longer in shortage, according to the FDA’s database that tracks drugs in limited supply. The agency’s shortage tracker for Mounjaro and...
View ArticleAdvisory committee votes in favor of Zevra Therapeutics' rare genetic disease...
A panel of outside advisors to the FDA voted 11-5 in favor of Zevra Therapeutics’ drug for a rare genetic condition called Niemann-Pick disease type C, saying that it is effective based on current...
View ArticleEisai’s new Leqembi data; Jim Wilson’s next move; Roivant dealmaker’s payday;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleExclusive: Biotech investor Sofinnova hires former Biogen medical chief
Maha Radhakrishnan, who left her post as chief medical officer at Biogen earlier this year, is now an executive partner at Sofinnova Investments, the firm exclusively told Endpoints News. Radhakrishnan...
View ArticleClik here to view.
Ultimovacs’ cancer vaccine UV1 flunks Phase 2 head and neck cancer trial
For a second time this year, Ultimovacs saw its stock crash after reporting its cancer vaccine failed in a Phase 2 study in head and neck squamous cell carcinoma. Topline data from the Phase 2 FOCUS...
View ArticleBayer details 3,200 job cuts so far, spotlights ‘momentum’ in pharma pipeline
Bayer is “on track” to realize the €2 billion in cost savings it’s aiming for in 2026, executives say, even as they report another quarter of “modest” performance across its crop science,...
View ArticleA new Apple Tree Partners biotech launches with $55M to make ‘pan-variant’...
Red Queen Therapeutics is emerging from stealth with $55 million from venture capital group Apple Tree Partners, and plans to develop treatments for a swathe of viral infections including Covid-19 and...
View Article